Literature DB >> 11734337

Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene.

Qin Wang1, David I R Holmes, Sue M Powell, Qi L Lu, Jonathan Waxman.   

Abstract

A PCR-based subtractive hybridisation technique was used to identify genes involved in stromal-epithelial interactions in prostate cancer. Eight genes were identified as being differentially expressed in benign prostatic fibroblast cells after stimulation with tumourigenic LNCaP conditioned media. One of these genes, protein tyrosine phosphatase CAAX2 (PTPCAAX2; also described as PTP4A and OV-1), has recently been shown to be oncogenic in hamster pancreatic epithelial cells. We show that PTPCAAX2 expression is up-regulated 4-fold in benign prostatic fibroblast cells 24 h after stimulation with LNCaP conditioned media and up-regulated 9-fold in prostatic tumour fibroblast cells. PTPCAAX2 overexpression was also detected in both androgen-dependent and androgen-independent prostate cancer cell lines and prostate tumour tissue, as determined by RT-PCR analysis and in situ hybridisation. These observations of PTPCAAX2 overexpression in prostate tumour cells and tissue suggest that PTPCAAX2 may potentially function as an oncogene in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11734337     DOI: 10.1016/s0304-3835(01)00703-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues.

Authors:  Carmen M Dumaual; George E Sandusky; Pamela L Crowell; Stephen K Randall
Journal:  J Histochem Cytochem       Date:  2006-09-06       Impact factor: 2.479

2.  PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.

Authors:  Michihiro Kobayashi; Yunpeng Bai; Yuanshu Dong; Hao Yu; Sisi Chen; Rui Gao; Lujuan Zhang; Mervin C Yoder; Reuben Kapur; Zhong-Yin Zhang; Yan Liu
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

Review 3.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

4.  Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels.

Authors:  Jeremy Gungabeesoon; Michel L Tremblay; Noriko Uetani
Journal:  Histochem Cell Biol       Date:  2016-03-25       Impact factor: 4.304

5.  Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.

Authors:  Yunpeng Bai; Zhi-Hong Yu; Sijiu Liu; Lujuan Zhang; Ruo-Yu Zhang; Li-Fan Zeng; Sheng Zhang; Zhong-Yin Zhang
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

6.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

7.  1H, 13C and 15N resonance assignments and secondary structure of the human protein tyrosine phosphatase, PRL-2.

Authors:  Hongjun Zhou; Marijo Gallina; Hongyuan Mao; Daniel Nietlispach; Stephen F Betz; Jacquelyn S Fetrow; Peter J Domaille
Journal:  J Biomol NMR       Date:  2003-12       Impact factor: 2.835

Review 8.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

10.  Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.

Authors:  Ni Dai; Ai-Ping Lu; Cheng-Chao Shou; Ji-You Li
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.